Neuromed Pharmaceuticals, of Conshohocken, Pa., promoted Sean Cunliffe to chief commercial officer.

NextGen Bioscience Inc., of London, named William H. Stimson to its international scientific advisory board.

Nile Therapeutics Inc., of Berkeley, Calif., appointed Jane Moffitt vice president of regulatory affairs.

Nucryst Pharmaceuticals, of Wakefield, Mass., appointed David B. Holtz vice president and chief financial officer.

Nventa Biopharmaceuticals Corp., of San Diego, named John Varian to its board.

Oncolin Therapeutics Inc., of Houston, named Randall K. Johnson to its scientific advisory board.

OncoVista Innovative Therapies Inc., of San Antonio, named Wolfram Rodatz CEO of its AdnaGen subsidiary.

Oragenics Inc., of Alachua, Fla., named Marc Siegel and Kevin Sills to its board.

Ovation Pharmaceuticals Inc., of Deerfield, Ill., named Samuel Yonren vice president of patient safety.

Oxford BioMedica, of Oxford, UK, appointed Alan Kingsman chairman and promoted Mike McDonald to CEO.

Parexel International Corp., of Boston, appointed Imogene Grimes vice president of data sciences strategic services.

Phytomedics Inc., of Jamesburg, N.J., named Laurie Smaldone Alsup president and CEO.

Quintiles Translational Corp., of Research Triangle Park, N.C., appointed Oren Cohen senior vice president of clinical research strategies.

Rib-X Pharmaceuticals Inc., of New Haven, Conn., named Nancy Motola senior vice president of regulatory affairs.

Sangamo BioSciences Inc., of Richmond, Calif., nominated Thomas G. Wiggans to its board.

Shire plc, of Basingstoke, UK, named Michael Rosenblatt to its board.

Speedel, of Basel, Switzerland, appointed Harald F. Schafer head of corporate communications and investor relations.

Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, appointed Arthur M. Bruskin to its board.

Tengion Inc., of East Norriton, Pa., appointed David P. Holveck to its board.

TetraLogic Pharmaceuticals, of Malvern, Pa., appointed Andrew Pecora chairman.

Transdel Pharmaceuticals Inc., of La Jolla, Calif., appointed Paul Finnegan chief medical officer and chief operating officer.

Tranzyme Pharma, of Research Triangle Park, N.C., named Philippa Charlton medical director of clinical development.

Traversa Therapeutics Inc., of La Jolla, Calif., appointed Barry Toyonaga senior vice president of business development.

Two River Group Holdings LLC, of New York, named Arie Belldegrun chairman and partner.

Upstream Biosciences Inc., of Vancouver, British Columbia, appointed Jeffery Bacha to its board.

Vermillion Inc., of Fremont, Calif., appointed John F. Hamilton to its board.